Cardiovascular disease diagnostic company CardioDx sets terms for $75 million IPO

By
A A A

CardioDx, which sells diagnostic tests for cardiovascular diseases, announced terms for its IPO on Monday. The Palo Alto, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, CardioDx would command a fully diluted market value of $282 million.

CardioDx, which was founded in 2003 and booked $7 million in sales for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol CDX. CardioDx initially filed confidentially on July 24, 2013. BofA Merrill Lynch and Jefferies are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CDX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

The Pumpkin Carvers
The Pumpkin Carvers                 
The Diamond Cutter
The Diamond Cutter                  

Stocks

Referenced

Most Active by Volume

25,640,628
  • $96.98 ▲ 2.39%
18,863,475
  • $45.1066 ▲ 0.62%
13,309,764
  • $70.29 ▲ 1.47%
11,777,658
  • $22.12 ▼ 10.88%
11,733,056
  • $40.38 ▼ 16.14%
11,238,801
  • $15.58 ▲ 0.39%
10,650,650
  • $11.11 ▲ 12.79%
9,964,923
  • $28.805 ▲ 1.00%
As of 7/23/2014, 10:22 AM